Radotinib Dihydrochloride

拉多替尼二盐酸盐

Report date: 2025/01/22 16:21:25
NME

Base Information

Drug NameRadotinib Dihydrochloride
Drug Alias Name雷度替尼雷多替尼拉多替尼盐酸拉多替尼Supect +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPlatelet-derived growth factor receptor inhibitorsBcr-Abl tyrosine kinase inhibitors
TargetsBcr-Abl tyrosine kinasePlatelet-derived growth factor receptor
Therapy Area/IndicationsPhiladelphia ChromosomeBone Marrow DiseasesHematologic Diseases +[8] 
Global Approved IndicationsLeukemia, Myelogenous, Chronic
Approved Indications in ChinaN/A
Original Approved Country/TerritorySouth Korea
Original Approved Date2012/01/05
Country/TerritoryUkraineThailandPhilippines +[10] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaNDA/BLA
Originator CompaniesIL-Yang Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesIL-Yang Pharmaceutical Co LtdIl-Yang Pharmco LtdIqvia Rds (Shanghai) Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsPhiladelphia ChromosomeParkinson DiseaseLeukemia, Myeloid, Chronic-Phase +[5] 
Inactive IndicationsBone Marrow DiseasesHematologic DiseasesLeukemia

Other Information

ATC CodeL01XE
Related LinksWikipediaDrugBank